Current treatment strategy and new agents in mantle cell lymphoma

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 25-32

  Ogura, Michinori ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Current treatment strategy; Mantle cell lymphoma; Promising new agents

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; BLINATUMOMAB; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; INOTUZUMAB OZOGAMICIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CELL CYCLE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL;

EID: 77955174254     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0607-8     Document Type: Review

References (53)

1. C Schmidt M Dreyling 2008 Therapy of mantle cell lymphoma: current standards and future strategies Hematol Oncol Clin North Am 22 953 963 10.1016/j.hoc.2008.07.001 18954745
2. RI Fisher S Dahlberg BN Nathwani, et al. 1995 A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood 85 1075 1082 1:CAS:528:DyaK2MXjs1Ojtbk%3D 7849295
3. Y Yatabe R Suzuki K Tobinai, et al. 2000 Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma Blood 95 2253 2261 1:CAS:528:DC%2BD3cXitFeitro%3D 10733493
4. CS Tam R Bassett C Ledesma, et al. 2009 Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood 113 4144 4152 10.1182/blood-2008-10-184200 1:CAS:528: DC%2BD1MXlvVGis7Y%3D 19168784
5. CH Geisler A Kolstad A Laurell, et al. 2008 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2687 2693 10.1182/blood-2008-03-147025 1:CAS:528:DC%2BD1cXht1SrtLfE 18625886
6. Hiddemann W, Lenz G, Weisenburger DD, et al. Mantle cell lymphoma. In: Mauch PM, Armitage J, Coiffier B, et al., editors. Non-Hodgkin's lymphomas. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 461-76.
7. OM Howard JG Gribben DS Neuberg, et al. 2002 Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival J Clin Oncol 20 1288 1294 10.1200/JCO.20.5.1288 1:CAS:528:DC%2BD38XisVWmurc%3D 11870171
8. G Lenz M Dreyling E Hoster, et al. 2005 Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J Clin Oncol 23 1984 1992 10.1200/JCO.2005.08.133 1:CAS:528: DC%2BD2MXjt1Cku7g%3D 15668467
9. Dreyling M, Meyer T, Hiddemann W. Mantle cell lymphoma. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of lymphoid malignancies. London: Martin Dunitz; 2001. p. 61-8.
10. E Vandenberghe C Ruiz de Elvira FR Loberiza, et al. 2003 Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries Br J Haematol 120 793 800 10.1046/j.1365-2141.2003.04140.x 12614212
11. AM Gianni M Magni M Martelli, et al. 2003 Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) Blood 102 749 755 10.1182/blood-2002-08-2476 1:CAS:528:DC%2BD3sXlslGiurs%3D 12663455
12. M Ogura Y Kagami H Taji, et al. 2003 Phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphomas Int J Hematol 77 503 511 10.1007/BF02986620 1:CAS:528:DC%2BD3sXls1Gmtro%3D 12841390
13. Y Oki M Ogura H Kato, et al. 2008 Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma Cancer Sci 99 179 184 1:CAS:528:DC%2BD1cXnsFWksg%3D%3D 17991293
14. JE Romaguera L Fayad MA Rodriguez, et al. 2005 High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with Rituximab plus hyper-CVAD alternating with Rituximab plus high-dose methotrexate and cytarabine J Clin Oncol 23 7013 7023 10.1200/JCO.2005.01.1825 1:CAS:528:DC%2BD2MXhtFCrsbnO 16145068
15. EM Epner J Unger T Miller, et al. 2007 A multi center trial of hyperCVAD + Rituxan in patients with newly diagnosed cell lymphoma Blood 110 387
16. J Mangel HA Leitch JM Connors, et al. 2004 Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis Ann Oncol 15 283 290 10.1093/annonc/mdh069 1:STN:280: DC%2BD2c%2FlvVamug%3D%3D 14760123
17. P Corradini M Ladetto F Zallio, et al. 2004 Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes J Clin Oncol 22 1460 1468 10.1200/JCO.2004.10.054 15084619
18. IF Khouri MS Lee RM Saliba, et al. 2003 Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma J Clin Oncol 21 4407 4412 10.1200/JCO.2003.05.501 1:CAS:528:DC%2BD2cXpsVajsrs%3D 14645431
19. M Wang Y Oki B Pro, et al. 2009 Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma Clin Oncol 27 5213 5218 10.1200/JCO.2009.21.8545 1:CAS:528:DC%2BD1MXhsFahsLjM
20. AK Gopal JG Rajendran SH Petersdorf, et al. 2002 High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood 99 3158 3162 10.1182/blood.V99.9.3158 1:CAS:528: DC%2BD38XjtlGqsro%3D 11964278
21. MR Smith L Zhang LI Gordon, et al. 2007 Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499 Blood 110 389
22. D Strumberg A Harstrick K Doll B Hoffmann S Seeber 1996 Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines Anticancer Drugs 7 415 421 10.1097/00001813-199606000-00007 1:CAS:528:DyaK28XkslWru7g%3D 8826610
23. CC Niemeyer B Bailey J Riefert 2004 SDX-105 (bendamustine is a clinically active chemotherapeutic agent with a distinct mechanism of action Proc Am Assoc Cancer Res 45 1129
24. LM Leoni B Bailey J Reifert, et al. 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309 317 10.1158/1078-0432.CCR-07- 1061 1:CAS:528:DC%2BD1cXoslKk 18172283
25. A Heider N Niederle 2001 Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas Anticancer Drugs 12 725 729 10.1097/00001813-200110000-00003 1:CAS:528:DC%2BD3MXosVKltLk%3D 11593053
26. JW Friedberg P Cohen L Chen, et al. 2008 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 204 210 10.1200/JCO.2007.12.5070 1:CAS:528:DC%2BD1cXitVWit70%3D 18182663
27. B Kahl PP Carbone N Bartlett J Leonard L Chen 2010 Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study Cancer 116 106 114 1:CAS:528:DC%2BC3cXitFGitbo%3D 19890959
28. K Bremer 2002 High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's- lymphomas J Cancer Res Clin Oncol 128 603 609 10.1007/s00432-002-0378-6 1:CAS:528:DC%2BD3sXptVyiuw%3D%3D 12458340
29. KS Robinson ME Williams RH van der Jagt, et al. 2008 Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma J Clin Oncol 26 4473 4479 10.1200/JCO.2008.17.0001 1:CAS:528:DC%2BD1cXht1ejurzP 18626004
30. MJ Rummel N Niederle G Maschmeyer A Banat U Von Gruenhagen 2009 Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the Stil (Study Group Indolent Lymphomas, Germany) Blood 114 405
31. M Ogura T Uchida K Ando, et al. 2009 Multicenter phase II study of bendamustine in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL) Blood 114 3694
32. A Nencioni F Grünebach F Patrone, et al. 2007 Proteasome inhibitors: antitumor effects and beyond Leukemia 21 30 36 10.1038/sj.leu.2404444 1:CAS:528:DC%2BD28XhtlSqur3P 17096016
33. A Mani EP Gelmann 2005 The ubiquitin-proteasome pathway and its role in cancer J Clin Oncol 23 4776 4789 10.1200/JCO.2005.05.081 1:CAS:528: DC%2BD2MXotFars7o%3D 16034054
34. KI Nakayama K Nakayama 2006 Ubiquitin ligases: cell-cycle control and cancer Nat Rev Cancer 6 369 381 10.1038/nrc1881 1:CAS:528:DC%2BD28XjslGitb4%3D 16633365
35. PG Richardson B Barlogie J Berenson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635
36. RC Kane R Dagher A Farrell, et al. 2007 Bortezomib for the treatment of mantle cell lymphoma Clin Cancer Res 13 5291 5294 10.1158/1078-0432.CCR-07-0871 1:CAS:528:DC%2BD2sXhtVCitL7F 17875757
37. S Vignot S Faivre D Aguirre, et al. 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525 537 10.1093/annonc/mdi113 1:STN:280:DC%2BD2M7kvVWmsQ%3D%3D 15728109
38. TE Witzig 2005 Current treatment approaches for mantle-cell lymphoma J Clin Oncol 23 6409 6414 10.1200/JCO.2005.55.017 1:CAS:528:DC%2BD2MXhtFWntbfK 16155027
39. F Bertoni E Zucca FE Cotter 2004 Molecular basis of mantle cell lymphoma Br J Haematol 124 130 140 10.1046/j.1365-2141.2003.04761.x 1:CAS:528: DC%2BD2cXhsVCktLw%3D 14687022
40. PJ Kurtin 1998 Mantle cell lymphoma Adv Anat Pathol 5 376 398 10.1097/00125480-199811000-00011 1:STN:280:DyaK1M7psFKisQ%3D%3D 10095879
41. PJ Kurtin KS Hobdaz S Yiesmer, et al. 1999 Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry Am J Pathol 112 319 329 1:STN:280:DyaK1MvgslGktg%3D%3D
42. TE Witzig SM Geyer I Ghobrial, et al. 2005 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 5347 5356 10.1200/JCO.2005.13.466 1:CAS:528:DC%2BD2MXpslOrtLk%3D 15983389
43. G Hess J Romaguera G Verhoef, et al. 2009 Phase 3 study of patients with relapsed, refractory mantle cell lymphoma treated with Temsirolimus compared with investigator's choice therapy J Clin Oncol 27 3822 3829 10.1200/JCO.2008.20.7977 1:CAS:528:DC%2BD1MXhtFaitrrN 19581539
44. PR Crocker A Varki 2001 Siglecs, sialic acids and innate immunity Trends Immunol 22 337 342 10.1016/S1471-4906(01)01930-5 1:CAS:528:DC%2BC3cXhtVWqsrw%3D 11377294
45. R Hanna GL Ong MJ Mattes 1996 Processing of antibodies bound to B-cell lymphomas and other hematological malignancies Cancer Res 56 3062 3068 1:CAS:528:DyaK28XjvFCkt7g%3D 8674063
46. JF DiJoseph DC Armellino ER Boghaert, et al. 2004 Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood 103 1807 1814 10.1182/blood-2003-07-2466 1:CAS:528:DC%2BD2cXhvVOhsbc%3D 14615373
47. A Advani B Coiffier MS Czuczman, et al. 2010 Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study J Clin Oncol 28 2085 2093 10.1200/JCO.2009.25.1900 1:CAS:528:DC%2BC3cXmtlSks78%3D 20308665
48. M Mack G Riethmueller P Kufer 1995 A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc Natl Acad Sci USA 92 7021 7025 10.1073/pnas.92.15.7021 1:CAS:528:DyaK2MXntVSktLg%3D 7624362
49. C Brandl C Haas S d'Argouges, et al. 2007 The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct Cancer Immunol Immunother 56 1551 1563 10.1007/s00262-007-0298-z 1:CAS:528:DC%2BD2sXotVKktr8%3D 17310380
50. R Bargou E Leo G Zugmaier, et al. 2008 Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974 977 10.1126/science.1158545 1:CAS:528:DC%2BD1cXpslWru70%3D 18703743
51. H Kaufmann M Raderer S Wohrer, et al. 2004 Antitumor activity of Rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 104 2269 2271 10.1182/blood-2004-03-1091 1:CAS:528: DC%2BD2cXovVegtr4%3D 15166030
52. TM Habermann IS Lossos G Justice, et al. 2009 Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma Br J Haematol 145 344 349 10.1111/j.1365-2141. 2009.07626.x 1:CAS:528:DC%2BD1MXlslOhsrc%3D 19245430
53. PL Zinzani T Witzig JM Vose 2008 Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: results of an international study (NHL-003) Blood 112 262